Stock HNSPF HANSOH PHARMACEUTICAL GROUP COMPANY LIMITED
Add to a list
To use this feature you must be a member
Log inSign up

Press Releases Hansoh Pharmaceutical Group Company Limited OTC Markets

Equities

HNSPF

KYG549581067

Market Closed - OTC Markets
Other stock markets
 03:54:35 2024-03-20 pm EDT 		5-day change 1st Jan Change
1.88 USD +19.75% Intraday chart for Hansoh Pharmaceutical Group Company Limited -.--% +2.73%
Apr. 30 Hansoh Pharmaceutical’s 2023 Profit Up 27% MT
Apr. 29 Hansoh Pharmaceutical Group Company Limited Announces Executive Changes, Effective April 29, 2024 CI

Press Releases

Search
See the results
Unlock all the news on all businesses: Never miss an investment opportunity again!
100% Free Registration
2023 CTOS, Hansoh Pharma HS-20093 Phase II clinical study design was selected into the International Connective Tissue Oncology Conference
AQ
Hansoh Pharmaceutical Group Co., Ltd. - The 24th China Patent Awards Ceremony was held, and Hansoh Pharma's Ametinib patent was awarded the China Patent Gold Award
AQ
Hansoh Pharmaceutical's Saint Relais is the first batch to be shipped nationwide, bringing a safe and long-lasting new option to CKD patients with renal anemia
AQ
SCYNEXIS and Hansoh Pharma Announce NMPA Acceptance of the New Drug Application for Ibrexafungerp in China
AQ
KiOmed Pharma and Hansoh Pharma Announce License Agreement for KioMedinevsone in China's Mainland, Macau and Taiwan
AQ
Hansoh Pharmaceutical : FINAL DIVIDEND FOR THE YEAR ENDED DECEMBER 31, 2021
PU
Hansoh Pharmaceutical : Pharma and OliX Pharmaceuticals Enter into Licensing and Collaboration Agreement to Develop and Commercialize siRNA Therapeutics in Greater China
AQ
SCYNEXIS : Announces Hansoh Pharma's Application to National Medical Products Administration (NMPA) in China for Phase 3 Trial of Ibrexafungerp for Treatment of Vulvovaginal Candidiasis (VVC)
AQ
SCYNEXIS : Announces Hansoh Pharma’s Application to National Medical Products Administration (NMPA) in China for Phase 3 Trial of Ibrexafungerp for Treatment of Vulvovaginal Candidiasis (VVC)
AQ
Hansoh Pharmaceutical : Accelerate Benefits for Hepatitis B Patients! Hansoh Pharma's New Class 1 Drug Hengmu (Tenofovir Amibufenamide Tablets) Prescribed for the First Time in China
AQ
Hansoh Pharmaceutical : VOLUNTARY ANNOUNCEMENT - NEW DRUG APPLICATION OF AMEILE IN FIRST LINE EGFR-MUTATED NON-SMALL CELL LUNG CANCER ACCEPTED BY THE NATIONAL MEDICAL PRODUCTS ADMINISTRATION
PU
Hansoh Pharmaceutical : VOLUNTARY ANNOUNCEMENT - FDA TENTATIVE APPROVAL OF "BORTEZOMIB FOR INJECTION"
PU
Hansoh Pharmaceutical : FORM OF PROXY FOR THE ANNUAL GENERAL MEETING TO BE HELD ON THURSDAY, JUNE 3, 2021
PU
Hansoh Pharmaceutical : VOLUNTARY ANNOUNCEMENT - DRUG REGISTRATION APPROVAL OF "LENALIDOMIDE CAPSULE"
PU
Hansoh Pharmaceutical : VOLUNTARY ANNOUNCEMENT - DRUG REGISTRATION APPROVAL OF "EMPAGLIFLOZIN TABLETS"
PU
Hansoh Pharmaceutical : INSIDE INFORMATION - LICENSE AGREEMENT WITH EQRX
PU
No results for this search
All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Filters

Search

Announcement Date

Since

Until

  1. Stock Market
  2. Equities
  3. 3692 Stock
  4. HNSPF Stock
  5. News Hansoh Pharmaceutical Group Company Limited
  6. Press Releases